Publications

Lancet JE, Cyr PL, Sacks NC, Chiarella MT, Louie AC, Cortes JE. CPX-351 enables administration of consolidation treatment in the outpatient setting and increases the time spent out of the hospital after completion of AML treatment compared with 7+3. American Society of Hematology Annual Meeting, San Diego CA, 2015.

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10. ISPOR 17th Annual European Congress 2014.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18^th Annual International Meeting, New Montreal Quebec, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16^th Annual European Congress, Amsterdam, Netherlands, 2014.

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Pinto DS, Nicholson G, Harrington RA, Cyr PL, Bhatt DL. CHAMPION PHOENIX Study economic results: Direct hospitalization costs of patients receiving clopidogrel or cangralor during percutaneous coronary intervention. American Heart Association QCOR conference, Baltimore, MD, 2014.

Jensen IS, Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin lymphoma in the United States: A budgetary impact analysis. Abstract C14. Academy of Managed Care Pharmacy 26^th Annual Meeting & Expo 2014.

Jensen IS, Halbert RJ, Grosvenor A, Swartz E, Rossi G, Naoshy S, et al. Incorporating stakeholder input into budget impact models to compare stem cell mobilization strategies. Abstract PCN43. ISPOR 18th Annual International Meeting, 2013.

Cyr P, Sidhu M, Hussain R, Hromin T, Jensen I, Kuan R. Dual-acting osmotic and stimulant laxative for bowel cleansing in an elderly population: A US payer budget impact analysis. Abstract PCN22. ISPOR 18th Annual International Meeting, 2013.